Mutations in the splicing factor SF3B1 are linked to frequent emergence of HLA-DRlow/neg monocytes in lower-risk myelodysplastic neoplasms

被引：0

作者：

Winter, Susann ^{[1
]}

Schneider, Marie ^{[2
]}

Oelschlaegel, Uta ^{[1
]}

Maggioni, Giulia ^{[3
,4
]}

Riva, Elena ^{[3
,4
]}

Raddi, Marco Gabriele ^{[5
]}

Bencini, Sara ^{[6
]}

Peruzzi, Benedetta ^{[6
]}

Choy, Desmond ^{[3
]}

Antunes Dos Reis, Rita ^{[3
]}

Guese, Esther ^{[7
,8
]}

Lischer, Christopher ^{[7
,8
]}

Vera, Julio ^{[7
,8
]}

Timms, Jessica A. ^{[3
]}

Sompairac, Nicolas ^{[3
]}

Sockel, Katja ^{[1
]}

Poloni, Antonella ^{[9
]}

Tunger, Antje ^{[10
,11
,12
,13
,14
,15
]}

Della Porta, Matteo Giovanni ^{[4
,16
]}

Santini, Valeria ^{[5
]}

Schmitz, Marc ^{[10
,11
,12
,13
,14
,15
,17
,18
]}

Platzbecker, Uwe ^{[2
,17
,18
,19
]}

Kordasti, Shahram ^{[3
,9
,20
]}

机构：

[1] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Fac Med Carl Gustav Carus, Dept Internal Med 1, Dresden, Germany

[2] Univ Leipzig Med Ctr, Dept Hematol Cellular Therapy & Hemostaseol & Inf, Leipzig, Germany

[3] Kings Coll London, Comprehens Canc Ctr, Sch Canc & Pharmaceut Sci, London, England

[4] IRCCS Humanitas Res Hosp, Milan, Italy

[5] Univ Florence, AOU Careggi Dept Expt & Clin Med, MDS Unit, Hematol, Florence, Italy

[6] AOU Careggi, Flow Cytometry Diagnost Ctr & Immunotherapy CDCI, Florence, Italy

[7] Friedrich Alexander Univ Erlangen Nurnberg, Lab Syst Tumor Immunol, Univ klinikum Erlangen, Erlangen, Germany

[8] Comprehens Canc Ctr Erlangen EMN, Deutsch Zent Immuntherapie, Erlangen, Germany

[9] Univ Politecn Marche, Dept Clin & Mol Sci, Ancona, Italy

[10] Tech Univ Dresden, Inst Immunol, Fac Med Carl Gustav Carus, Dresden, Germany

[11] Natl Ctr Tumor Dis NCT, Dresden, Germany

[12] Tech Univ Dresden, German Canc Res Ctr DKFZ, Dresden, Germany

[13] Tech Univ Dresden, Fac Med, Dresden, Germany

[14] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dresden, Germany

[15] Helmholtz Zentrum Dresden Rossendorf HZDR, Dresden, Germany

[16] Humanitas Univ, Dept Biomed Sci, Milan, Italy

[17] German Canc Consortium DKTK, Partner Site Dresden, Heidelberg, Germany

[18] German Canc Res Ctr, Heidelberg, Germany

[19] German MDS Study Grp D MDS, Leipzig, Germany

[20] Guys Hosp, Haematol Dept, London, England

来源：

LEUKEMIA | 2024年 / 38卷 / 06期

关键词：

IMMUNOSUPPRESSIVE THERAPY; MDS;

D O I：

10.1038/s41375-024-02249-z

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1427 / 1431

页数：5

共 35 条

[31] Mutations in the RNA Splicing Factor SF3B1 drive endocrine therapy resistance and confer a targetable replication stress response defect through PARP inhibition
Bland, Phil
Saville, Harry
Read, Abigail
Wai, Patty
Muirhead, Gareth
Curnow, Lucinda
Nieminuszczy, Jadwiga
Ravindran, Nivedita
John, Marie
Hedayat, Somaieh
Barker, Holly
Wright, James
Yu, Lu
Mavrommati, Ioanna
Peck, Barrie
Allen, Mark
Gazinska, Patrycja
Pemberton, Helen
Gulati, Aditi
Nash, Sarah
Noor, Farzana
Guppy, Naomi
Roxanis, Ioannis
Barlow, Samantha
Kalirai, Helen
Coupland, Sarah
Broderick, Ronan
Alsafadi, Samar
Houy, Alexandre
Stern, Marc-Henri
Pettit, Stephen
Choudhary, Jyoti
Haider, Syed
Niedzwiedz, Wojciech
Lord, Christopher
Natrajan, Rachael
CANCER RESEARCH, 2023, 83 (05)
[32] Validation of a Prognostic Model and the Impact of SF3B1, DNMT3A, and Other Mutations in 289 Genetically Characterized Lower Risk MDS Patient Samples
Bejar, Rafael
Stevenson, Kristen
Caughey, Bennett
Abdel-Wahab, Omar
Galili, Naomi
Garcia-Manero, Guillermo
Kantarjian, Hagop M.
Raza, Azra
Steensma, David P.
Levine, Ross L.
Neuberg, Donna
Ebert, Benjamin L.
BLOOD, 2011, 118 (21) : 443 - 443
[33] Clinical outcomes by SF3B1 mutation status in patients (pts) with lower-risk myelodys-plastic syndrome (LR-MDS) retreated with erythropoiesis-stimulating agents (ESAs).
Makinde, Adeola Y.
Garcia-Manero, Guillermo
Matsuno, Rayna K.
McBride, Ali
Brown, Thomas D.
Idryo, Danny
Broome, Ronda
Herriman, Autumn
Wilkinson, Kristiana
Walters, Sheetal
Schrag, Andrew
Mohammed, Hina
Izano, Monika A.
Mukherjee, Sudipto
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[34] Myelodysplastic Neoplasms (MDS) with Ring Sideroblasts or SF3B1 Mutations: The Improved Clinical Utility of World Health Organization and International Consensus Classification 2022 Definitions, a Single-Centre Retrospective Chart Review
Mortuza, Shamim
Chin-Yee, Benjamin
James, Tyler E.
Chin-Yee, Ian H.
Hedley, Benjamin D.
Ho, Jenny M.
Saini, Lalit
Lazo-Langner, Alejandro
Schenkel, Laila
Bhai, Pratibha
Sadikovic, Bekim
Keow, Jonathan
Sangle, Nikhil
Hsia, Cyrus C.
CURRENT ONCOLOGY, 2024, 31 (04) : 1762 - 1773
[35] Targeted Next-Generation Sequencing of TP53, BIRC3, NOTCH1, SF3B1, and ATM Identifies a Significant Proportion of Lower-Risk Chronic Lymphocytic Leukemia with Unfavorable Prognostic Indicators
Kwok, Brian
Yung, Aine
Reddy, Prashanti
Xu, Yin
Chan, Alex
Lyle, Derek
BLOOD, 2018, 132

← 1 2 3 4 →